March 30, 2017
Matinas BioPharma adds life sciences executive to its board
Matinas BioPharma has appointed a life sciences executive to its Board of Directors.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
March 30, 2017
Probiodrug’s profit in line with company’s expectations
Probiodrug AG, a Germany based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer`s disease (AD), has announced its financial results for the twelve-month period ending 31 December 2016.
March 30, 2017
Oncodesign reports €0.6M profit for 2016
Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has reported its full-year 2016 results.
March 30, 2017
Amryt reports €7.8M loss for 2016, enters 2017 with new in-license drug and two clinical trials
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has reported its final results for the year ended 31 December 2016.
March 30, 2017
FDA accepts Novartis’s BLA for acute lymphoblastic leukemia treatment
US Food and Drug Administration (FDA) has accepted the Novertis’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).
March 29, 2017
Roche’s subsidiary Genentech wins FDA approval for MS and PPMS
U.S. Food and Drug Administration (FDA) has approved Roche’s subsidiary Genentech’s Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
March 29, 2017
Faron Pharmaceuticals reports €9.2M loss for 2016
Faron Pharmaceuticals, the clinical stage biopharmaceutical company, has reported full year audited results for the year ended 31 December 2016.
March 29, 2017
Allergy Therapeutics reports €7.9M for second half od 2016
Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016.
March 29, 2017
Alliance Pharma’s profit up to €20M
Alliance Pharma, the specialty pharmaceutical company, has announced results for the year ended 31 December 2016.
March 29, 2017
Stada’s 2016 profit down 22%
The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.